Akari Therapeutics Stock (AKTX) Soars on Revolutionary Cancer Therapy Patent Filing

BREAKING: Biotech disruptor Akari Therapeutics just dropped a patent bomb that sent its stock skyrocketing—because nothing makes investors happier than exclusive rights to potentially life-saving technology.

THE PATENT PLAY

Akari's latest filing covers a novel cancer therapy approach that could reshape treatment protocols. While traditional oncology treatments often come with brutal side effects, this new methodology targets cancer cells with precision—cutting through biological complexities and bypassing healthy tissue damage.

MARKET REACTION

Investors piled into AKTX as news broke, proving once again that nothing moves biotech stocks faster than the words 'patent' and 'cancer' in the same sentence. Because who needs actual revenue when you've got intellectual property dreams?

THE BOTTOM LINE

This isn't just another biotech hype cycle—it's a calculated move to secure market dominance before clinical trials even begin. Because in the pharmaceutical game, the real therapy might be for shareholder portfolios rather than patients.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

As of 2:24 p.m. EDT, the shares were up about 6% to $0.80.

The patent application seeks to protect Akari’s antibody drug conjugate (ADC) platform, its targeted cancer treatment system. The system uses antibodies to find cancer cells and delivers a drug called PH1 to disrupt how these cells edit their genetic instructions. This stops them from making proteins they need to grow and survive.

Akari said this new cancer therapy is different from others because instead of targeting a single mutation or cancer type, the treatment targets a basic process called alternative splicing. This process explains how cells edit genetic instructions to make different versions of proteins from the same gene.

Furthermore, Akari noted that the new patent, if granted, WOULD strengthen its proprietary position. The company sees the new technology as a chance to become a leader in the race to develop therapies that target a wide range of cancers.

A Possible Change in Fortune?

Meanwhile, Akari’s recent update follows the biotech company’s report of a net loss of $3.7 million during the first quarter of 2025. However, the company had recorded a bigger $5.6 million net loss during the same period last year.

The new development also comes nearly a year after Akari Therapeutics finalized its merger with Peak Bio, a clinical-stage biopharma company. Akari also recently hired a new CEO to redirect the company’s focus towards developing its novel ADC platform.

What are the Best Biotech Stocks to Buy?

On TipRanks, Akari Therapeutics’ shares have a Strong Buy consensus recommendation based on three Buys assigned by Wall Street analysts over the past three months. The average AKTX price target of $4.53 also suggests an expansive 467% growth potential from its current price.

However, as The Graph below shows, TipRanks’ Stock Comparison tool also provides insight into other biotech stocks investors can snap up right now.